Biosimilar Guidance Silent On Industry's Biggest Questions
The U.S. Food and Drug Administration's newly released guidance on how it will review biosimilars was a relief to an industry that's been waiting two years for clarity. But experts say...To view the full article, register now.
Already a subscriber? Click here to view full article